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Differential ketogenic diet-induced shift 
in CSF lipid/carbohydrate metabolome 
of pediatric epilepsy patients with optimal vs. 
no anticonvulsant response: a pilot study
Susan A. Masino1 , David N. Ruskin1* , Natalie R. Freedgood1 , Marie Lindefeldt2 and Maria Dahlin2 
Abstract 
Background: The low carbohydrate, high fat ketogenic diet can be an effective anticonvulsant treatment in some 
pediatric patients with pharmacoresistant epilepsy. Its mechanism(s) of action, however, remain uncertain. Direct 
sampling of cerebrospinal fluid before and during metabolic therapy may reveal key changes associated with differ-
ential clinical outcomes. We characterized the relationship between seizure responsiveness and changes in lipid and 
carbohydrate metabolites.
Methods: We performed metabolomic analysis of cerebrospinal fluid samples taken before and during ketogenic 
diet treatment in patients with optimal response (100% seizure remission) and patients with no response (no seizure 
improvement) to search for differential diet effects in hallmark metabolic compounds in these two groups. Opti-
mal responders and non-responders were similar in age range and included males and females. Seizure types and 
the etiologies or syndromes of epilepsy varied but did not appear to differ systematically between responders and 
non-responders.
Results: Analysis showed a strong effect of ketogenic diet treatment on the cerebrospinal fluid metabolome. Lon-
gitudinal and between-subjects analyses revealed that many lipids and carbohydrates were changed significantly by 
ketogenic diet, with changes typically being of larger magnitude in responders. Notably, responders had more robust 
changes in glucose and the ketone bodies β-hydroxybutyrate and acetoacetate than non-responders; conversely, 
non-responders had significant increases in fructose and sorbose, which did not occur in responders.
Conclusions: The data suggest that a differential and stronger metabolic response to the ketogenic diet may predict 
a better anticonvulsant response, and such variability is likely due to inherent biological factors of individual patients. 
Strategies to boost the metabolic response may be beneficial.
Keywords: Acetoacetate, Anticonvulsant, β-hydroxybutyrate, Cerebrospinal fluid, Glucose, Ketogenic diet, Pediatric 
epilepsy
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Introduction
Epilepsy affects 1 in 26 people across the lifespan [1], 
and 25–30% of patients suffer uncontrolled seizures 
in spite of pharmacotherapy [2]. In addition, the inci-
dence of side effects of anticonvulsants is high, and 
can lead to cessation of medications [3, 4]. Ketogenic 
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diet (KD) is a metabolic therapy that employs a high-
fat, low-carbohydrate, moderate-protein formulation 
developed initially to mimic the metabolic state of 
fasting [5, 6]: it is established as anticonvulsant [7], 
antiepileptic [8], neuroprotective [9], and particularly 
useful in some specific diagnoses [10] and in refrac-
tory epilepsy [11, 12].
Fasting and adhering to a KD each produce hall-
mark changes in blood ketone bodies (increased) and 
glucose (decreased) but it has remained unclear how 
these changes relate to beneficial effects. For instance, 
blood ketone body levels do not always correlate with 
anticonvulsant effects [13], and in general anticonvul-
sant benefits of ketones versus glucose in clinical and 
laboratory work is mixed and still under active investi-
gation and debate [14]. Furthermore, mechanistic links 
between these metabolic blood chemistry changes 
and anticonvulsant effects are unclear. Clearly many 
systemic changes occur with dietary therapy, making 
it difficult to sort out key mechanisms of efficacy. To 
date a number of studies have examined changes in 
blood metabolites aside from ketone bodies and glu-
cose, typically examining a limited number of prede-
termined compounds to address specific hypotheses 
[15–21]. While cerebrospinal fluid (CSF) is signifi-
cantly more difficult to collect than blood, analysis of 
CSF metabolites may be more relevant to KD mecha-
nisms in epilepsy [22–25].
Metabolomics is a liquid chromatography/gas chro-
matography/mass spectroscopy-based technique for 
quantifying all detectable small molecule metabolites, 
such as carbohydrates, small lipids, amino acids, etc. 
and has been used to describe biological phenotypes in 
epilepsy [26] and other neurological disorders [27] as 
well as dietary treatments [28]. Extant metabolomics 
studies of serum and ketogenic diet have described 
compensatory adaptations in amino acid metabolism 
[29] and correlations between metabolites and fecal 
microbiota [30] in experimental rodents. In general, 
metabolomic analysis of CSF could be a powerful tool 
for discovering KD-related mechanisms. Here we pre-
sent novel data based on a set of CSF samples collected 
twice from pediatric patients with refractory seizures 
– once before KD treatment and once during KD treat-
ment. This experimental design enables each patient to 
serve as their own control, and thus the ability to com-
pare baselines and changes in the metabolome to the 
observed clinical response. A metabolomic analysis of 
carbohydrates and lipids could relate the biochemical 
effects of the KD to the magnitude of the clinical (anti-
convulsant) response, and enables a review of predic-
tors of KD efficacy.
Methods
Ethics
The study was approved by the Ethics Committee of the 
Karolinska Hospital and the informed consent of the par-
ents and, when possible, patients, was obtained.
Patients
Patients have been described in detail previously [22, 23]. 
Briefly, the study was part of a larger prospective open 
trial on the efficacy and safety of the KD in children with 
epilepsy. The patients were enrolled consecutively as they 
attended the Epilepsy Outpatient Clinic and the decision 
to start the KD was made.
Inclusion criteria were an age of 1–18 years, pharmaco-
logically refractory epilepsy with a prior trial of at least 
three antiepileptic drugs, consideration of epilepsy sur-
gery, no medical contraindications, family and patient 
able to cooperate in a KD trial, and approval for perform-
ing two lumbar punctures before and during KD. Parents 
and other caregivers made daily notes on the number and 
type(s) of seizures on seizure calendars routinely used 
in the clinic. Parental reports were compared with the 
observations of seizure type and frequency made by the 
epilepsy nurses during hospitalization. A subgroup of 27 
children were selected based on the most differentiated 
clinical outcome – namely those observed as seizure-
free seizure and those with no observed improvement. 
Five of the patients became seizure-free and were clas-
sified as having “optimal response” and five patients had 
no detectable seizure reduction and were classified as 
having “no response” (see Table 1). In these ten included 
children metabolomics analysis with a focus on changes 
in carbohydrates and lipids. These patients all had varia-
ble levels of intellectual disability except for one who had 
autism spectrum disorder; patients were a mix of verbal 
and non-verbal.
Study design
This pre-KD/during KD retrospective design, performed 
between 1998 and 2002 at the Neuropediatric Depart-
ment of the Astrid Lindgren Children’s Hospital, (Karo-
linska Hospital), has been described in detail previously 
[22, 23]. To initiate the diet, patients were hospitalized 
during a 4–5 day stay. The 1st CSF sampling was col-
lected via lumbar puncture obtained immediately before 
diet start and the 2nd CSF sampling was performed dur-
ing a 2  day inpatient stay about 3  months after KD ini-
tiation when major fine-tuning adjustments of the diet 
were made. During the 2nd sampling the patients were 
on 3:1 or 4:1 KD ratio (Table  1). All lumbar punctures 
were performed in the morning, around 8 AM, soon after 
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breakfast. During both lumbar punctures, four mL CSF 
was collected: samples with visible blood content were 
not used. Aliquots were immediately cold-centrifuged, 
supernatant collected, frozen, and stored at − 70 °C. Prior 
studies have shown that metabolites stored at this tem-
perature are expected to remain stable for decades [32, 
33]. Serum β-hydroxybutyrate (β-HB) levels were meas-
ured the same morning before breakfast of the 2nd lum-
bar puncture and analyzed consecutively.
The diet followed a standardized protocol for the clas-
sic KD, which is a slightly modified version of the pro-
tocol of the Johns Hopkins Hospital [34]. Most patients 
were started at a 4:1 (fats:(proteins + carbohydrates)) 
ratio. A minimum of 1 g/kg body weight per day of pro-
tein was used. At diet start supplements of vitamins and 
minerals were given to all patients as well as carnitine 
(100 mg/kg body weight per day). All calculations of the 
amount of calories and the nutrient composition of the 
menus of the diet were made for the individual child by a 
specially trained dietician.
The parents were educated on all aspects of the diet 
by a specialized dietician, neuropediatrician, and keto 
nurse during a 4–5 days inpatient stay at diet start. The 
parents were carefully instructed on the importance of 
being accurate in preparing the menus of the diet, and on 
keeping detailed diaries. Dietary compliance was moni-
tored by daily testing of urine ketones at home by parents 
with data reported to nurses, and also by blood testing 
for β-hydroxybutyrate during frequent visits with the diet 
team consisting of nurse, dietician and neuropediatrician. 
Members of the team had frequent (sometimes daily) tel-
ephone consultations with parents on how to manage the 
diet. Also, diaries were discussed with the team during 
clinic visits at 1 and 3 months of treatment. Medications 
were not changed during the study, with the exception of 
slight decreases in some children.
Metabolomics
Frozen CSF samples (20 total) were sent to Metabolon 
(Durham, North Carolina) for metabolomics analysis 
in 2014. Samples were prepared and extracted. Inter-
nal standards were added to every analyzed sample as 
an internal quality control; samples were split into frac-
tions for ultra-high performance liquid chromatogra-
phy-tandem mass spectrometry (UPLC-MS/MS) with 
positive ionization, UPLC-MS/MS with negative ioni-
zation, and gas chromatography–mass spectrometry 
(GC-MS). The UPLC-MS/MS platform utilizes Waters 
Acquity UPLC with Waters UPLC BEH C18 or BEH 
Amide 2.1 × 100 mm, 1.7 μm columns and a ThermoSci-
entific Q-Exactive high resolution/accurate mass spec-
trometer interfaced with a heated electrospray ionization 
(HESI-II) source and Orbitrap mass analyzer operated at 
35,000 mass resolution. The GC-MS platform utilizes a 
Thermo-Finnigan Trace DSQ fast-scanning single-quad-
rupole MS using electron impact ionization operated at 
unit mass resolving power (scan range 50–750 m/z), with 
a 5% diphenyl/95% dimethyl polysiloxane fused silica col-
umn (20 m × 0.18 mm ID; 0.18 um film thickness) with 
helium as carrier gas and a temperature ramp from 60° 
to 340 °C in a 17.5 min period. Metabolites were identi-
fied by automated comparison of the ion features in the 
experimental samples to a reference library of chemical 
standard entries that include retention time, molecular 
Table 1 Patient demographics, sorted by clinical response
Seizure types classified according to the International League Against Epilepsy (ILAE) classification [31]. “Diet ratio” indicates the (fat:(protein + carbohydrate)) ratio of 
the KD at time of 2nd lumbar puncture. Abbreviations: AED antiepileptic drug, T/C tonic/clonic, L-G Lennox-Gastaux syndrome, VPA valproic acid, CZP clonazepam, CLB 
clobazam, LTG lamotrigine, PRI primidone, TPM topiramate, PB phenobarbital
Characteristics of 5 patients with optimal seizure reduction (no detected seizures)
 sex age Epilepsy type(s) Seizure type(s) Etiology/syndrome AEDs Diet ratio
 M 4.5 generalized Myoclonic, generalized T/C Doose syndrome VPA, CZP 4:1
 F 4.8 generalized Myoclonic, tonic, absence L-G syndrome CLB 3:1
 M 5.1 generalized Myoclonic, tonic Down’s syndrome VPA, LTG 4:1
 F 5.8 generalized Myoclonic, generalized T/C Cortical dysplasia (polymicrogyria) none 3:1
 F 9.0 focal Focal without impaired awareness Cortical dysplasia PRI, VPA 4:1
 Mean: 5.8
Characteristics of 5 patients with no observed change in seizures
 M 4.0 generalized Myoclonic, tonic, epileptic spasms Inverted duplicated chromosome 15, L-G syndrome LTG, TPM 4:1
 M 6.0 generalized Epileptic spasms, generalized T/C L-G syndrome VPA, LTG 3:1
 M 6.3 generalized Myoclonic, absence, generalized T/C Infantile spasms, L-G syndrome VPA, CLB 4:1
 F 6.7 generalized Generalized T/C Unknown LTG, PB, TPM 4:1
 M 10.1 generalized Myoclonic, atonic Agenesi corpus callosum, other CNS malformations VPA, CZP 4:1
 Mean: 6.6
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weight (m/z), preferred adducts, and in-source frag-
ments as well as associated MS spectra. Identification 
of known chemical entities was based on comparison to 
metabolomic library entries of ~ 4500 purified standards. 
Raw data (ion counts) for each metabolite were scaled 
so that the median equaled one; missing values (non-
detections) were imputed with half the minimum value. 
Statistical analysis (performed by Metabolon) included 
ANOVA, and paired and unpaired t-tests as appropriate. 
False discovery rate (q) was calculated for multiple com-
parisons: here we consider q < 0.10 to indicate high confi-
dence in a result, and 0.10 < q < 0.20 to indicate moderate 
confidence.
Results
The patient group included all five children with 100% 
seizure reduction (“optimal response”) and all five 
patients with no seizure reduction; demographics of the 
patient group are given in Table 1. Patients with optimal 
seizure response and no observed seizure remission to 
KD treatment had similar age ranges and included both 
males and females. Seizure types and the etiology of the 
epilepsy or epilepsy syndrome varied and did not appear 
to differ systematically between patients with an optimal 
vs. no observable clinical response. Similarly, anticonvul-
sant drug treatment did not appear to differ systemati-
cally between the two groups, nor did KD ratio. Statistical 
analysis was not performed on these factors due to vari-
ability, overlap in diagnostic categories and small sample 
size.
In CSF samples from these patients, 271 metabolites 
were identified. We focused on analyzing CSF com-
pounds in the lipid and carbohydrate families (49 and 
25 compounds detected, respectively. In the lipid fam-
ily 25/49 compounds changed significantly (comparing 
baseline to during KD) in patients with an optimal vs. no 
observable clinical response; in the carbohydrate family, 
15/25 changed significantly in optimal or no observable 
clinical response (Table  2). Considering both families 
together, there was a strong trend (p = 0.066) for more 
compounds to change baseline-to-KD in patients with an 
optimal vs. no observable clinical response.
CSF lipids and their metabolites were mostly 
increased by KD treatment (Table  2), including the 
hydroxylated derivatives and carnitine esters of 
medium- and short-chain fatty acids. The ketone bod-
ies acetoacetate and β-hydroxybutyrate were increased 
many-fold, and although the ketone body acetone 
was not itself detected, its metabolite 1,2-propan-
ediol [35] was detected and elevated significantly. 
There were large increases in trimethylamine N-oxide 
(a gut microbiotic metabolite of dietary carnitine and 
lecithin) and glycocholate (a gut microbiota-modified 
bile acid). There were decreases in methylmalonyl-
carnitine (involved in fatty acid synthesis) and glycerol 
3-phosphate (a triglyceride metabolite). Many of these 
changes were significant only in optimal responders. 
Regarding compounds that were significantly changed 
in both patients with an optimal vs. no observable 
clinical response (e.g. hexanoyl- and acetyl-carnitine, 
3-hydroxyoctanoate, trimethylamine N-oxide), exami-
nation of the fold changes in means reveals larger mag-
nitude changes in optimal responders.
Not surprisingly, since a KD greatly reduces dietary 
carbohydrates, CSF sugars and their metabolites/deriva-
tives during KD therapy changed greatly from base-
line to during KD (Table  3). Some carbohydrates were 
decreased, including glucose (significant only in optimal 
responders) and the glycemic indicator 1,5-anhydroglu-
citol [36]. A number of hexoses and pentoses, however, 
were increased. Elevated pyruvate in brain was previ-
ously noted in rodents eating a KD [37]. Notably, sorbose 
and fructose were significantly increased only in patients 
with no clinical response.
As for between-subjects comparisons of CSF metabo-
lites in patients with an optimal vs. no clinical response 
during KD treatment, no compounds survived applica-
tion of a false-discovery rate correction. However, several 
showed differences that were significant with uncor-
rected t-tests (Table 4), and these demonstrated a pattern 
that supported the within-subjects comparison. Ketone 
bodies and some fatty acids and hydroxylated fatty acids 
were several-fold higher in patients with optimal vs. no 
clinical response. In addition, glucose, sorbose, and fruc-
tose were lower in optimal responders.
Between-subject comparisons of CSF metabolites in 
patients with optimal vs. no clinical response in base-
line samples revealed only one compound that was sig-
nificant with an uncorrected t-test at p < 0.05: the hexose 
mannose, higher in patients with no clinical response 
(Table 4).
Statistical analysis was further focused on the hall-
mark changes in biochemistry within the lipid and 
carbohydrate families, namely the ketone bodies and 
glucose. We applied two-by-two ANOVAs to these 
CSF metabolites with clinical response to KD and 
time as factors. There were no baseline differences 
between the groups (locants are overlapping in Fig. 1). 
As expected, ketone bodies (β-hydroxybutyrate and 
acetoacetate) were elevated and glucose was lowered 
during KD treatment; however, all these responses 
were significantly smaller in the patients with no clini-
cal response vs. those with optimal response (Fig.  1). 
Serum levels of β-hydroxybutyrate during KD were also 
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Table 2 Ketogenic diet-induced changes in lipids
Ratios are fold changes from during KD compared to before KD. Compounds are grouped by compound family, and by optimal response ratio within that family. 
Significant increases are indicated with bold, significant decreases with italics. False-discovery rates: *0.10 < q < 0.20, **0.05 < q < 0.10, ***q < 0.05. 7-HOCA – 7-alpha-
hydroxy-3-oxo-4-cholestenoate, CMPF – 3-carboxy-4-methyl-5-propyl-2-furanpropanoate, GPC glycerol-3-phosphocholine, GPE glycero-3-phosphoethanolamine
During diet/Prediet
Compound Family Compound optimal response no response
Ketone Bodies 1,2-propanediol 29.16*** 7.47**
Acetoacetate 130.8*** 67.5***
β-hydroxybutyrate 175.5*** 57.4***






Carnitine Metabolism Carnitine 0.99 1.19
Deoxycarnitine 2.00 1.35
3-dehydrocarnitine 61.96*** 108.5***






Medium Chain Fatty Acids Nonanoic acid 0.97 1.19
Dodecanoic acid 1.05 0.98
Decanoic acid 1.14* 1.12
Octanoic acid 1.90 1.15
Heptanoic acid 2.24 0.73
Hexanoic acid 3.29 1.49
Phospholipid Metabolism Choline 0.96 0.94
Phosphoethanolamine 1.02 1.26
Choline phosphate 1.47 2.50
Trimethylamine N-oxide 715.1** 375.3**
Amide Fatty Acid Oleamide 0.99 16.48
Dicarboxylate Fatty Acids 2-hydroxyglutarate 2.05 1.07
CMPF 8.81* 2.61
Triglyceride Metabolism Glycerol 3-phosphate 0.82** 0.86
Glycerol 1.22 0.89
Lysophospholipids 1-oleoyl-GPC (18:1) 0.46* 2.27
1-docosahexaenoyl-GPE (22:6) 0.93 0.84
1-oleoyl-GPE (18:1) 1.29 1.51
1-palmitoyl-GPC (16:0) 3.16 1.90
Inositol Metabolism Scyllo-inositol 0.84 0.81
Myo-inositol 1.12 0.81
Amino Fatty Acids 2-aminoheptanoate 1.38 1.67
2-aminooctanoate 631.4 9.24*
Fatty Acid Synthesis 2-methylmalonylcarnitine 0.64*** 0.69*
Polyunsaturated Fatty Acid Docosahexaenoate (22:6n3) 2.05 1.07
Primary Bile Acid Metabolism Glycocholate 12.08* 2.44
Sphingolipid Metabolism Palmitoyl sphingomyelin (d18:1/16:0) 2.66* 1.73
Corticosteroids Cortisone 0.73** 1.19
Cortisol 0.98 1.65
Androgenic Steroid Androstenediol (3β,17β) disulfate 6.31 6.02
Sterols 7-α-HOCA 0.95 0.88*
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significantly lower in patients with no clinical response 
(3.2 ± 0.4 mM) vs. those with optimal response 
(5.2 ± 0.1 mM, p < 0.01), expected as CSF ketone body 
levels track blood levels [38–42].
Follow-up data are available on all patients. In the 5 
patients who rapidly acquired seizure freedom, “opti-
mal responders”, the KD was continued between 2 years 
and 4.6 years. In three of these the KD was tapered and 
several years after discontinuation of the diet they were 
still seizure-free. In two patients, however, seizures 
came back during tapering: in one there are very few 
seizures but in the other the seizures were as bad as 
before KD. In the five patients with no seizure response, 
the diet was tapered after 3–4 months in three patients, 
but parents of two patients persevered with the KD 
because of improved communication and better alert-
ness. Dietary treatment was continued for 2–3 years 
with these behavioral improvements persisting.
Discussion
We characterized KD-induced changes in the CSF lipid/
carbohydrate metabolome in pediatric epilepsy patients 
with the most distinct clinical behavioral responses 
at 3 months: either no detectable seizures (optimal 
response) or no detectable change in the frequency of 
refractory seizures. A major finding from this analysis, 
supported by longitudinal and between-subjects analy-
ses, is that those patients who had an optimal response 
had a stronger metabolic response to the KD than those 
patients who showed no seizure improvement. This 
effect was evident by a larger number of KD-changed 
compounds and a larger magnitude change in most of 
those compounds in optimal responders – including glu-
cose and the ketone bodies. While this pattern might be 
interpreted to indicate that the patients with no clinical 
response were less compliant, there is some evidence to 
suggest this is not true. For example, diet compliance was 
Table 3 Diet-induced changes in carbohydrates
Ratios are fold changes from during KD compared to before KD. Compounds are grouped by compound family, and by optimal response ratio within that family. 
Significant increases are indicated with bold, significant decreases with italics. False-discovery rates: *0.10 < q < 0.20, **0.05 < q < 0.10, ***q < 0.05
During diet/Prediet
Compound Family Compound optimal response no response




















Aminosugar Metabolism Erythronate 0.84* 0.77**
N-acetylneuraminate 0.98 0.93
Glucuronate 1.04 1.04
Advanced Glycation End-product Erythrulose 1.3 0.58*
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described as good by caretakers and medical personnel. 
Furthermore, all patients with no clinical response (as 
well those with optimal response) had striking elevations 
of CSF ketone bodies during KD compared to pre-diet 
(and high blood ketone bodies during KD), confirming 
adherence to a KD that precipitated a shift to ketone-
based metabolism. Thus, these differences may be due 
to inherent biological variability in metabolic response. 
We cannot rule out, however, that some external dietary 
factors (exact ratio of KD administered, types of fat or of 
protein, etc.) could be involved.
Of paramount interest is the identification of com-
pounds that could be mechanistically involved in the 
anticonvulsant effect of a robust metabolic response. The 
Table 4 Between-subject differences, optimal v. no response, on and before ketogenic diet
Ratios are fold difference between patients with an optimal vs. no clinical response. Only compounds with p < 0.10 are listed. *0.05 < p < 0.10, **p < 0.05
During KD responders / non-responders
Compound family Compound
Ketone Bodies β-hydroxybutyrate 3.24**
acetoacetate 3.88**
1,2-propanediol 4.74*
Monohydroxy Fatty Acids γ-hydroxybutyrate 2.06**
3-hydroxyoctanoate 2.61**
Medium Chain Fatty Acid hexanoic acid 2.79**






Acyl Carnitines acetylcarnitine 0.72*
 Corticosteroids cortisol 1.36*
 Hexoses mannose 0.72**
 Tetroses erythrulose 0.34*
Fig. 1 Hallmark changes in ketone bodies β-hydroxybutyrate (left) and acetoacetate (middle) and glucose (right) are greater in CSF from patients 
with optimal response compared to those with no response. Data are scaled to one (indicated by dashed lines); means and standard errors are 
shown. See text for quantified β-hydroxybutyrate level. ANOVA group-x-time interactions: β-hydroxybutyrate F = 6.8, p = 0.031; acetoacetate 
F = 11.6, p = 0.009; glucose F = 5.8, p = 0.043. There were also significant main effects of time and patient group for each metabolite. ** p < 0.01, *** 
p < 0.001 compared to pre-KD; †p < 0.05, ††p < 0.01, †††p < 0.001 compared to optimal responder during KD
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eponymous products of a KD are an obvious candidate 
[14]. Beyond being a more efficient fuel for in oxida-
tive metabolism and mitochondrial health, ketone bod-
ies are putative signaling molecules in several pathways 
that should improve the state of hyperexcitable brain 
tissue, including inhibitory ion channels [43], vesicular 
glutamate release [44], inflammation [45], nicotinamide 
adenine dinucleotide oxidation state [46], and histone 
deacetylases [47]. It was realized in the earliest KD stud-
ies that some threshold level of blood ketone bodies 
needed to be reached for beneficial outcomes [48, 49]. 
Beyond that, however, the connection of elevated blood 
ketone bodies and anticonvulsant effects clinically has 
been controversial, described as correlated [50–52] or 
not [53]. Studies have noted that some individual patients 
benefit despite not being in ketosis [54–56] or have 
described a correlation only at certain lengths of KD 
treatment [55, 57].
Besides elevating brain ketone body levels via the liver, 
low glucose appears to have direct effects in brain. Mildly 
lowered glucose promotes an autocrine inhibition in 
pyramidal neurons in vitro based on the neuromodulator 
adenosine [58]. This same mechanism is invoked by KD 
treatment [59] and is anti-seizure [60]. Similarly, partial 
block of glycolysis with 2-deoxyglucose tempers epilep-
tiform activity in vitro [61] and seizures in vivo in some 
models [62]. Low glycemic index diets can be anticonvul-
sant in the absence of ketosis [63, 64], and low glucose 
rather than elevated ketone bodies seems to underlie the 
anticonvulsant action of caloric restriction [65]. At the 
other end of the glycolytic pathway, elevated pyruvate 
was significant in optimal responders only, which may 
indicate decreased usage due to increased acetyl-CoA 
production from ketone bodies.
Acetyl-carnitine, associated with dietary red meat [28] 
is involved in synthesis of acetyl-CoA. Although little 
work has been done with seizures directly [66], this mol-
ecule is thought to be neuroprotective, neurotrophic, and 
antioxidant. Notably, acetyl-carnitine is well-tolerated as 
a dietary supplement [67].
Conversely, this metabolomics analysis revealed some 
elevated compounds that may be mechanistically detri-
mental to the efficacy of a KD. KD-related elevations in 
fructose and sorbose occur in patients with no clinical 
response and not those with optimal response. Because 
fructose and sorbose can be metabolized to fructose-
6-phosphate, these KD-related changes could augment 
glycolytic metabolites downstream of glucose. Combined 
with a smaller reduction in glucose itself in patients with 
no clinical response, this pattern might indicate that 
substantial amounts of acetyl-coA are still entering the 
Kreb’s cycle from the glycolytic pathway. This state may 
offset the enhanced efficiency of adenosine triphosphate 
production during ketolysis, undermining the beneficial 
effects of the KD-related metabolic state presumably 
occurring with full force in optimal responders.
Many detected compounds likely reflect a stronger 
metabolic response to the KD in optimal responders 
without being mechanistically involved in a better anti-
convulsant response. For instance, increases in trimeth-
ylamine N-oxide is to be expected in a diet rich in meat, 
fish, and eggs; changes in glycocholate and methylmalo-
nyl carnitine comport with a high fat diet; decreased 
glycerol 3-phosphate could be due to increased shunt-
ing into glycolysis (via dihydroxyacetone phosphate) to 
augment this underpowered pathway – none of these 
metabolites are thought to have signaling properties in 
brain. 3-hydroxyoctanoate is a signaling molecule with 
specific receptors expressed in adipocytes but not brain 
[68]. γ-hydroxybutyrate also acts on specific receptors 
(GPR172A), and is used exogenously as an abused hyp-
notic/sedative drug. However, antagonism of GPR172A is 
anticonvulsant; conversely, activation is used to produce 
an animal model of absence seizures [69] making higher 
γ-hydroxybutyrate unlikely to be involved in a better 
anticonvulsant response to the KD. It was hypothesized 
that elevated β-hydroxybutyrate might mediate the mild 
euphoria found during fasting and sometimes during KD 
[70] by acting pharmacologically like γ-hydroxybutyrate; 
however, elevated γ-hydroxybutyrate itself may underlie 
this effect.
These findings can be related to prior clinical stud-
ies of the plasma metabolome, and some changes found 
in plasma were not present in these CSF samples. For 
instance, KD did not elevate cortisol in CSF, whereas it 
has been reported to do so in plasma; these latter stud-
ies were, however, in rheumatoid arthritis patients [19, 
53]. Cappuccio et al. reported elevated plasma hydroxy-
butyryl- and acetyl-carnitine and lower methylmalonyl-
carnitine in KD-treated glucose transporter 1 deficient 
patients [16], similar to the present results. Also, Sch-
oeler et  al. demonstrated a stronger β-hydroxybutyrate 
response to KD treatment in patients with optimal clini-
cal response vs. those with no response; however, they 
also reported that optimal responders had higher base-
line CSF β-hydroxybutyrate and octanoyl- and acetyl-
carnitine [21]. We did not replicate those findings, and 
in fact showed a trend for lower initial acetyl-carnitine 
in optimal responders (and a significant increase during 
KD was also specific to optimal responders – showing 
a strong regulation by KD). These discrepancies could 
be due to true differences between plasma and CSF, or 
might reflect dissimilar definitions of patients with opti-
mal response or no clinical response.
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We acknowledge some limitations to the present study. 
The number of subjects is low, which reduces statistical 
power. Also, we are unaware of any clinical study that 
describes effects of the presently-used anticonvulsants 
on CSF levels of our metabolites of interest, so if and 
how these drugs had any effect remains unknown. Last, 
metabolomics was not performed on plasma, which 
was collected but lost in a freezer accident. This could 
have indicated correlations between CSF and plasma 
and possibly identified blood-born predictors of clinical 
response.
Conclusions
In a small but valuable clinical cohort with pre- and 
post-KD CSF sampling, we found a more effective anti-
convulsant response correlated with a stronger cen-
tral metabolic response at 3  months of KD treatment. 
Such samples present a special opportunity as studies 
with sequential lumbar punctures in pediatric patients 
are rare, but allow for within-subjects analysis. This 
study extends and complements prior work on mono-
amine and amino acid neurotransmitters in CSF [22, 
23]. Focused studies of specific metabolites are valu-
able, but the unpredicted changes found here (such as 
KD-elevated levels of hexoses only in non-reponders) 
highlight the importance of casting a wide net. Further 
work is needed and could determine more quantita-
tively if a strong central metabolic response early in KD 
treatment predicts an ultimately effective anticonvul-
sant outcome, information that may be useful in deci-
sions about treatment adjuvants, adjustments and/or 
continuation. In addition, a blood-based correlate that 
predicts efficacy would be extremely valuable because 
CSF collection is necessarily invasive. It is worth noting 
that some of the relevant metabolites (ketone bodies, 
1,2-propanediol, glycerol 3-phosphate) are detectable 
with 1H or 31P nuclear magnetic resonance spectros-
copy. For those whose poor anticonvulsant response 
may due to inherent biological factors, on possibility is 
that KD treatment could be amplified by manipulating 
hallmark metabolic changes directly – for example sup-
plementing with relevant molecules, e.g. ketone bodies 
(via precursors such as ketone esters, medium chain 
triglycerides, or coconut oil) or acetyl-carnitine.
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